Cencora, Inc. (COR) Stock Analysis
Healthcare · Medical Distribution
Sell if holding. Momentum 4.0/10 is below the 5.0 floor at $305.52 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 4.7): -1.5; Concentration risk — Customer: top ten customers (66.0%).
Cencora is one of the largest global pharmaceutical distribution companies, distributing brand-name, specialty, and generic pharmaceuticals to healthcare providers in the U.S. and over 50 countries. It is the primary distributor for Walgreens in the U.S. and Boots in the U.K.... Read more
Sell if holding. Momentum 4.0/10 is below the 5.0 floor at $305.52 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 4.7): -1.5; Concentration risk — Customer: top ten customers (66.0%). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.3/10, high confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 6d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomerWalgreens and Boots25%10-K Item 1A: 'Walgreens and Boots together accounted for approximately 25% of our revenue in fiscal 2025'
- HIGHCustomertop ten customers66%10-K Item 1A: 'Our top ten customers, including governmental agencies, represented approximately 66% of revenue in fiscal 2025.'
Material Events(8-K, last 90d)
- 2026-03-17Item 5.02HIGHCFO James F. Cleary announced retirement effective June 30, 2026. Departure not the result of any disagreement on company operations, policies, or practices. No successor named.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 4.0/10 is below the 5.0 floor at $305.52 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 4.7): -1.5; Concentration risk — Customer: top ten customers (66.0%). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $290.52. Score 5.3/10, high confidence.
Take-profit target: $350.54 (+14.7% upside). Prior stop was $290.52. Stop-loss: $290.52.
Concentration risk — Customer: top ten customers (66.0%); Leverage penalty (D/E 4.7): -1.5; Earnings in 6 days (event risk).
Cencora, Inc. trades at a P/E of 37.4 (forward 15.9). TrendMatrix value score: 6.7/10. Verdict: Sell.
18 analysts cover COR with a consensus score of 4.1/5. Average price target: $403.
What does Cencora, Inc. do?Cencora is one of the largest global pharmaceutical distribution companies, distributing brand-name, specialty, and...
Cencora is one of the largest global pharmaceutical distribution companies, distributing brand-name, specialty, and generic pharmaceuticals to healthcare providers in the U.S. and over 50 countries. It is the primary distributor for Walgreens in the U.S. and Boots in the U.K. under agreements extending through 2029 and 2031 respectively.